The effects of tubulazole, a new synthetic microtubule inhibitor on experimental neoplasms.
Tubulazole, a new synthetic microtubule inhibitor in vitro, is tested in vivo upon three experimental neoplasms: MO4 sarcoma, L1210 leukemia and TA3 carcinoma. The compound is tested using different treatment schedules upon different inoculation routes of the cells. All trials show the compound to have distinct antineoplastic properties in vivo by prolonging the median survival time. The best treatment schedule seems to be an intermittent one, i.e. treatment every fourth day starting 1 day after tumor inoculation. Comparison with cyclophosphamide and vincristine is in favor of tubulazole for treating TA3 mammacarcinoma, while cyclophosphamide and vincristine give somewhat better results upon L1210 leukemia. The effects of tubulazole and cyclophosphamide upon MO4 fibrosarcoma are comparable, while vincristine has no effect in this system. Worthwhile noting is that all the in vivo, as well as in vitro, activity of tubulazole resides in the cis isomer, while the trans isomer has no effect at all.
D000818:Animals; D003520:Cyclophosphamide / Q000627:therapeutic use; D004148:Dioxolanes / Q000627:therapeutic use*; D004149:Dioxoles / Q000627:therapeutic use*; D007939:Leukemia L1210 / Q000188:drug therapy; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000401:mortality; D012513:Sarcoma, Experimental / Q000188:drug therapy; D014750:Vincristine / Q000627:therapeutic use
D004148:Dioxolanes; D004149:Dioxoles; D014750:Vincristine; C040422:tubulazole; D003520:Cyclophosphamide